Scandion Oncology board member Michel Ducreux steps down, joins advisory board
Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced that Michel Ducreux, board member since May 2024 is stepping down from his position. Ducreux is also co-chair of the European Society For Medical Oncology Gastrointestinal Congress 2024 and 2025 organization and member of the clinical guidelines committee. He is stepping down due to the scientific society’s guidelines prohibiting such board positions.
Michel Ducreux, MD, PhD, will continue to support Scandion in an advisory role on the company’s advisory board, where his extensive knowledge and expertise can continue to benefit Scandion.
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: [email protected]
About this information
The information was submitted for publication, through the agency of the contact persons set out above, on July 1, 2024, at 17.30 CET.
About Scandion Oncology
Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
